Mesenchymal stem cell therapy for breast cancer‑related secondary lymphedema (Review)

Han,Shunxin; Cai,Junrong; Zhang,Yuteng; Lu,Feng

doi:10.3892/mco.2025.2868

Mesenchymal stem cell therapy for breast cancer‑related secondary lymphedema (Review)

Authors:
- Shunxin Han
- Junrong Cai
- Yuteng Zhang
- Feng Lu
View Affiliations

Affiliations: Department of Plastic and Cosmetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: June 23, 2025 https://doi.org/10.3892/mco.2025.2868
Article Number: 73
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Secondary lymphedema, affecting ~15‑30% of patients who survive breast cancer, is a common consequence following treatment. At present, there is no gold standard for the treatment of breast cancer‑related lymphedema (BCRL). Conventional methods such as physiotherapy and surgery demonstrate a limited effectiveness in mitigating lymphatic swelling or discomfort and fail to provide substantial physiological improvement or a definitive cure for lymphedema. However, stem cell therapy has garnered notable attention due to its regenerative potential and its capacity to modulate inflammatory processes. Mesenchymal stem cell (MSC) therapies exhibit promise in ameliorating BCRL by addressing edema, promoting lymphangiogenesis and mitigating fibrosis. It is shown that MSC therapy promotes the regeneration of autologous lymphatic networks and improves vascular conditions in rodent tail and hindlimb lymphedema models, which offers relief from lymphedema symptoms including limb volume asymmetry and impaired lymphatic drainage. However, currently, due to a lack of a universally recognized or standardized treatment regimen for BCRL, there is a need for additional clinical studies featuring larger sample sizes and extended follow‑up periods to further investigate this prospective therapeutic modality. The present review aims to provide guidance for further research and therapeutic interventions following the results observed in both preclinical and clinical settings. The present study investigated the pathogenesis of secondary lymphedema, previous advancements in stem cell therapy for this condition and an analysis of persisting challenges.

View Figures

View References

1	Grada AA and Phillips TJ: Lymphedema: Pathophysiology and clinical manifestations. J Am Acad Dermatol. 77:1009–1020. 2017.PubMed/NCBI View Article : Google Scholar
2	Hu LR and Pan J: Adipose-derived stem cell therapy shows promising results for secondary lymphedema. World J Stem Cells. 12:612–620. 2020.PubMed/NCBI View Article : Google Scholar
3	Vargo M, Aldrich M, Donahue P, Iker E, Koelmeyer L, Crescenzi R and Cheville A: Current diagnostic and quantitative techniques in the field of lymphedema management: A critical review. Med Oncol. 41(241)2024.PubMed/NCBI View Article : Google Scholar
4	McLaughlin SA, Brunelle CL and Taghian A: Breast cancer-related lymphedema: Risk factors, screening, management, and the impact of locoregional treatment. J Clin Oncol. 38:2341–2350. 2020.PubMed/NCBI View Article : Google Scholar
5	Aguilera-Eguía RA, Seron P, Gutiérrez-Arias R and Zaror C: Which physical therapy intervention is most effective in reducing secondary lymphoedema associated with breast cancer? Protocol for a systematic review and network meta-analysis. BMJ Open. 12(e065045)2022.PubMed/NCBI View Article : Google Scholar
6	Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, Wang Q, Yan Y, Yu Y, Zhong Y, et al: Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer. 126:4023–4031. 2020.PubMed/NCBI View Article : Google Scholar
7	Jariwala P and Kaur N: A descriptive study on prevalence of arm/shoulder problems and its impact on quality of life in breast cancer survivors. Indian J Cancer. 58:201–206. 2021.PubMed/NCBI View Article : Google Scholar
8	Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl). 135:584–590. 2022.PubMed/NCBI View Article : Google Scholar
9	Hasenoehrl T, Palma S, Ramazanova D, Kölbl H, Dorner TE, Keilani M and Crevenna R: Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis. Support Care Cancer. 28:3593–3603. 2020.PubMed/NCBI View Article : Google Scholar
10	DiSipio T, Rye S, Newman B and Hayes S: Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis. Lancet Oncol. 14:500–515. 2013.PubMed/NCBI View Article : Google Scholar
11	Dessources K, Aviki E and Leitao MM Jr: Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer. 30:252–260. 2020.PubMed/NCBI View Article : Google Scholar
12	Bruno C, Cesta CE, Hjellvik V, Ulrichsen SP, Bjørk MH, Esen B, Gillies MB, Gissler M, Havard A, Karlstad Ø, et al: Corrigendum to Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: A multinational cohort study [eClinicalMedicine 70 (2024) 102531/DOI: 10.1016/j.eclinm.2024.102531]. EClinicalMedicine 81: 103139, 2025.
13	Hassan AM, Fisher CS and Hassanein AH: ASO author reflections: navigating the nuances of lymphedema prevention with immediate lymphatic reconstruction. Ann Surg Oncol: Apr 20, 2025 (Epub ahead of print).
14	Bouhali S, Merchant F, Karni RJ, Gutierrez C and Rasmussen JC: 3D rendering and analysis of dermal backflow as an early indicator of cancer-acquired lymphedema using RGB-D and near-infrared fluorescence lymphatic imaging. Proc SPIE 12930, Medical Imaging 2024: Clinical and Biomedical Imaging, 1293008, 2024.
15	Frueh FS, Körbel C, Gassert L, Müller A, Gousopoulos E, Lindenblatt N, Giovanoli P, Laschke MW and Menger MD: High-resolution 3D volumetry versus conventional measuring techniques for the assessment of experimental lymphedema in the mouse hindlimb. Sci Rep. 6(34673)2016.PubMed/NCBI View Article : Google Scholar
16	Wang N, Liao C, Cao X, Nishimura M, Brackenier YWE, Yurt M, Gao M, Abraham D, Alkan C, Iyer SS, et al: Spherical echo-planar time-resolved imaging (sEPTI) for rapid 3D quantitative T₂^* and susceptibility imaging. Magn Reson Med. 93:121–137. 2025.PubMed/NCBI View Article : Google Scholar
17	Xie K, Jiang H, Chen X, Ning Y, Yu Q, Lv F, Liu R, Zhou Y, Xu L, Yue Q and Peng J: Multiparameter MRI-based model integrating radiomics and deep learning for preoperative staging of laryngeal squamous cell carcinoma. Sci Rep. 15(16239)2025.PubMed/NCBI View Article : Google Scholar
18	Rogan S, Taeymans J, Luginbuehl H, Aebi M, Mahnig S and Gebruers N: Therapy modalities to reduce lymphoedema in female breast cancer patients: A systematic review and meta-analysis. Breast Cancer Res Treat. 159:1–14. 2016.PubMed/NCBI View Article : Google Scholar
19	Gao Y, Ma T, Han M, Yu M and Wang X, Lv Y and Wang X: Effects of acupuncture and moxibustion on breast cancer-related lymphedema: A systematic review and meta-analysis of randomized controlled trials. Integr Cancer Ther. 20(15347354211044107)2021.PubMed/NCBI View Article : Google Scholar
20	Keeley V: Advances in understanding and management of lymphoedema (cancer, primary). Curr Opin Support Palliat Care. 11:355–360. 2017.PubMed/NCBI View Article : Google Scholar
21	Raju A and Chang DW: Vascularized lymph node transfer for treatment of lymphedema: A comprehensive literature review. Ann Surg. 261:1013–1023. 2015.PubMed/NCBI View Article : Google Scholar
22	No authors listed. Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review: Erratum. Medicine (Baltimore). 97(e0670)2018.PubMed/NCBI View Article : Google Scholar
23	Toyserkani NM, Christensen ML, Sheikh SP and Sørensen JA: Stem cells show promising results for lymphoedema treatment-a literature review. J Plast Surg Hand Surg. 49:65–71. 2015.PubMed/NCBI View Article : Google Scholar
24	Das M, Mayilsamy K, Mohapatra SS and Mohapatra S: Mesenchymal stem cell therapy for the treatment of traumatic brain injury: Progress and prospects. Rev Neurosci. 30:839–855. 2019.PubMed/NCBI View Article : Google Scholar
25	Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM and Caplan AI: Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med. 4(22)2019.PubMed/NCBI View Article : Google Scholar
26	Jensen MR, Simonsen L, Karlsmark T and Bülow J: Microvascular filtration is increased in the forearms of patients with breast cancer-related lymphedema. J Appl Physiol (1985). 114:19–27. 2013.PubMed/NCBI View Article : Google Scholar
27	Castilla DM, Liu ZJ, Tian R, Li Y, Livingstone AS and Velazquez OC: A novel autologous cell-based therapy to promote diabetic wound healing. Ann Surg. 256:560–572. 2012.PubMed/NCBI View Article : Google Scholar
28	Wariss BR, de Souza Abrahão K, de Aguiar SS, Bergmann A and Thuler LCS: Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer. Maturitas. 101:51–56. 2017.PubMed/NCBI View Article : Google Scholar
29	Cong C, Rao C, Ma Z, Yu M, He Y, He Y, Hao Z, Li C, Lou H and Gao D: ‘Nano-lymphatic’ photocatalytic water-splitting for relieving tumor interstitial fluid pressure and achieving hydrodynamic therapy†. Mater Horiz. 7:3266–3274. 2020.
30	Zhuang T, Lei Y, Chang JJ, Zhou YP, Li Y, Li YX, Yang YF, Chen MH, Meng T, Fu SM, et al: A2AR-mediated lymphangiogenesis via VEGFR2 signaling prevents salt-sensitive hypertension. Eur Heart J. 44:2730–2742. 2023.PubMed/NCBI View Article : Google Scholar
31	Schoofs H, Daubel N, Schnabellehner S, Grönloh MLB, Palacios Martínez S, Halme A, Marks AM, Jeansson M, Barcos S, Brakebusch C, et al: Dynamic cytoskeletal regulation of cell shape supports resilience of lymphatic endothelium. Nature. 641:465–475. 2025.PubMed/NCBI View Article : Google Scholar
32	Chen CE, Chiang NJ, Perng CK, Ma H and Lin CH: Review of preclinical and clinical studies of using cell-based therapy for secondary lymphedema. J Surg Oncol. 121:109–120. 2020.PubMed/NCBI View Article : Google Scholar
33	Avraham T, Zampell JC, Yan A, Elhadad S, Weitman ES, Rockson SG, Bromberg J and Mehrara BJ: Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 27:1114–1126. 2013.PubMed/NCBI View Article : Google Scholar
34	Nishioka T, Katayama KI, Kumegawa S, Isono K, Baba T, Tsujimoto H, Yamada G, Inoue N and Asamura S: Increased infiltration of CD4⁺ T cell in the complement deficient lymphedema model. BMC Immunol. 24(42)2023.PubMed/NCBI View Article : Google Scholar
35	Uemura K, Katayama KI, Nishioka T, Watanabe H, Yamada G, Inoue N and Asamura S: Dynamics of immune cell infiltration and fibroblast-derived IL-33/ST2 axis induction in a mouse model of post-surgical lymphedema. Int J Mol Sci. 26(1371)2025.PubMed/NCBI View Article : Google Scholar
36	Ogata F, Fujiu K, Matsumoto S, Nakayama Y, Shibata M, Oike Y, Koshima I, Watabe T, Nagai R and Manabe I: Excess lymphangiogenesis cooperatively induced by macrophages and CD4(+) T cells drives the pathogenesis of lymphedema. J Invest Dermatol. 136:706–714. 2016.PubMed/NCBI View Article : Google Scholar
37	Ogino R, Yokooji T, Hayashida M, Suda S, Yamakawa S and Hayashida K: Emerging anti-inflammatory pharmacotherapy and cell-based therapy for lymphedema. Int J Mol Sci. 23(7614)2022.PubMed/NCBI View Article : Google Scholar
38	Higgins ET, Busse WW, Esnault S, Christian BT, Klaus DR, Bach JC, Frye CJ and Rosenkranz MA: Fueling the fire in the lung-brain axis: The salience network connects allergen-provoked TH17 responses to psychological stress in asthma. Brain Behav Immun. 128:276–288. 2025.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
39	De Castro V, Abdellaoui O, Dehecq B, Ndao B, Mercier-Letondal P, Dauvé A, Garnache-Ottou F, Adotévi O, Loyon R and Godet Y: Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies. Cancer Immunol Immunother. 74(200)2025.PubMed/NCBI View Article : Google Scholar
40	Li H, Wu Y, Song XH, Li CX, Cai Y and Chen C: Expression of Th1 and Th2 cytokines in serum of patients with lupus nephritis. Mod Prev Med. 40 746:2013.
41	Zhu Q, Yang H, Altaf F, Wu N, Hu Y, Su L, Li J, Liu J, Wang G, Igbiriki DG, et al: SOCS8 deficiency models MAFLD-like progression in the zebrafish gut-liver axis. Water Biology and Security. Elsevier, pp100414, 2025.
42	Lee SO and Kim IK: Molecular pathophysiology of secondary lymphedema. Front Cell Dev Biol. 12(1363811)2024.PubMed/NCBI View Article : Google Scholar
43	Duhon BH, Phan TT, Taylor SL, Crescenzi RL and Rutkowski JM: Current mechanistic understandings of lymphedema and lipedema: Tales of fluid, fat, and fibrosis. Int J Mol Sci. 23(6621)2022.PubMed/NCBI View Article : Google Scholar
44	Peña Quián Y, Hernández Ramirez P, Batista Cuellar JF, Perera Pintado A and Coca Pérez MA: Lymphoscintigraphy for the assessment of autologous stem cell implantation in chronic lymphedema. Clin Nucl Med. 40:217–219. 2015.PubMed/NCBI View Article : Google Scholar
45	Toyserkani NM, Jensen CH, Tabatabaeifar S, Jørgensen MG, Hvidsten S, Simonsen JA, Andersen DC, Sheikh SP and Sørensen JA: Adipose-derived regenerative cells and fat grafting for treating breast cancer-related lymphedema: Lymphoscintigraphic evaluation with 1 year of follow-up. J Plast Reconstr Aesthet Surg. 72:71–77. 2019.PubMed/NCBI View Article : Google Scholar
46	Jørgensen MG, Toyserkani NM, Hansen FCG, Thomsen JB and Sørensen JA: Prospective validation of indocyanine green lymphangiography staging of breast cancer-related lymphedema. Cancers (Basel). 13(1540)2021.PubMed/NCBI View Article : Google Scholar
47	Kern S, Eichler H, Stoeve J, Klüter H and Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 24:1294–1301. 2006.PubMed/NCBI View Article : Google Scholar
48	Yu SJ, Kim HJ, Lee ES, Park CG, Cho SJ and Jeon SH: β-catenin accumulation is associated with increased expression of nanog protein and predicts maintenance of MSC self-renewal. Cell Transplant. 26:365–377. 2017.PubMed/NCBI View Article : Google Scholar
49	Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P and Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 13:4279–4295. 2002.PubMed/NCBI View Article : Google Scholar
50	Le Blanc K and Ringdén O: Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 262:509–525. 2007.PubMed/NCBI View Article : Google Scholar
51	Hassanein AH, Sinha M, Neumann CR, Mohan G, Khan I and Sen CK: A murine tail lymphedema model. J Vis Exp. (10.3791/61848)2021.PubMed/NCBI View Article : Google Scholar
52	Arruda G, Ariga S, de Lima TM, Souza HP and Andrade M: A modified mouse-tail lymphedema model. Lymphology. 53:29–37. 2020.PubMed/NCBI
53	Yu J and Guo W: Modern medical progress of peripheral lymphedema treated by integrated traditional Chinese and western medicine. Adv Clin Med. 12:4228–4234. 2022.
54	Hou C, Wu X and Jin X: Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema: A prospective controlled study in patients with breast cancer related lymphedema. Jpn J Clin Oncol. 38:670–674. 2008.PubMed/NCBI View Article : Google Scholar
55	Zhou H, Wang M, Hou C, Jin X and Wu X: Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema. Jpn J Clin Oncol. 41:841–846. 2011.PubMed/NCBI View Article : Google Scholar
56	Ismail AM, Abdou SM, Abdelnaby AY, Hamdy MA, El Saka AA and Gawaly A: Stem cell therapy using bone marrow-derived mononuclear cells in treatment of lower limb lymphedema: A randomized controlled clinical trial. Lymphat Res Biol. 16:270–277. 2018.PubMed/NCBI View Article : Google Scholar
57	Weigand A, Beier JP, Arkudas A, Al-Abboodi M, Polykandriotis E, Horch RE and Boos AM: The arteriovenous (AV) loop in a small animal model to study angiogenesis and vascularized tissue engineering. J Vis Exp. (54676)2016.PubMed/NCBI View Article : Google Scholar
58	Boos AM, Loew JS, Weigand A, Deschler G, Klumpp D, Arkudas A, Bleiziffer O, Gulle H, Kneser U, Horch RE and Beier JP: Engineering axially vascularized bone in the sheep arteriovenous-loop model. J Tissue Eng Regen Med. 7:654–664. 2013.PubMed/NCBI View Article : Google Scholar
59	Weigand A, Horch RE, Boos AM, Beier JP and Arkudas A: The arteriovenous loop: Engineering of axially vascularized tissue. Eur Surg Res. 59:286–299. 2018.PubMed/NCBI View Article : Google Scholar
60	Robering JW, Al-Abboodi M, Titzmann A, Horn I, Beier JP, Horch RE, Kengelbach-Weigand A and Boos AM: Tissue engineering of lymphatic vasculature in the arteriovenous loop model of the rat. Tissue Eng Part A. 27:129–141. 2021.PubMed/NCBI View Article : Google Scholar
61	Levi B, Glotzbach JP, Sorkin M, Hyun J, Januszyk M, Wan DC, Li S, Nelson ER, Longaker MT and Gurtner GC: Molecular analysis and differentiation capacity of adipose-derived stem cells from lymphedema tissue. Plast Reconstr Surg. 132:580–589. 2013.PubMed/NCBI View Article : Google Scholar
62	Dhumale P, Nielsen JV, Hansen ACS, Burton M, Beck HC, Jørgensen MG, Toyserkani NM, Haahr MK, Hansen ST, Lund L, et al: CD31 defines a subpopulation of human adipose-derived regenerative cells with potent angiogenic effects. Sci Rep. 13(14401)2023.PubMed/NCBI View Article : Google Scholar
63	Ackermann M, Wettstein R, Senaldi C, Kalbermatten DF, Konerding MA, Raffoul W and Erba P: Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res. 102:78–85. 2015.PubMed/NCBI View Article : Google Scholar
64	Hayashida K, Yoshida S, Yoshimoto H, Fujioka M, Saijo H, Migita K, Kumaya M and Akita S: Adipose-derived stem cells and vascularized lymph node transfers successfully treat mouse hindlimb secondary lymphedema by early reconnection of the lymphatic system and lymphangiogenesis. Plast Reconstr Surg. 139:639–651. 2017.PubMed/NCBI View Article : Google Scholar
65	Ogino R, Hayashida K, Yamakawa S and Morita E: Adipose-derived stem cells promote intussusceptive lymphangiogenesis by restricting dermal fibrosis in irradiated tissue of mice. Int J Mol Sci. 21(3885)2020.PubMed/NCBI View Article : Google Scholar
66	Dai T, Jiang Z, Cui C, Sun Y, Lu B, Li H, Cao W, Chen B, Li S and Guo L: The roles of podoplanin-positive/podoplanin-negative cells from adipose-derived stem cells in lymphatic regeneration. Plast Reconstr Surg. 145:420–431. 2020.PubMed/NCBI View Article : Google Scholar
67	Jørgensen MG, Toyserkani NM, Jensen CH, Andersen DC, Sheikh SP and Sørensen JA: Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up. Stem Cells Transl Med. 10:844–854. 2021.PubMed/NCBI View Article : Google Scholar
68	Yang S, Sun Y and Yan C: Recent advances in the use of extracellular vesicles from adipose-derived stem cells for regenerative medical therapeutics. J Nanobiotechnology. 22(316)2024.PubMed/NCBI View Article : Google Scholar
69	Kasseroller RG and Brenner E: Effectiveness of manual lymphatic drainage in intensive phase I therapy of breast cancer-related lymphedema-a retrospective analysis. Support Care Cancer. 32(5)2023.PubMed/NCBI View Article : Google Scholar
70	Tashiro K, Yoshioka Y and Ochiya T: Extracellular vesicles from adipose-derived stem cells relieve extremity lymphedema in mouse models. Plast Reconstr Surg. 152:1011–1021. 2023.PubMed/NCBI View Article : Google Scholar
71	Cheng X, Henick BS and Cheng K: Anticancer therapy targeting cancer-derived extracellular vesicles. ACS Nano. 18:6748–6765. 2024.PubMed/NCBI View Article : Google Scholar
72	Yuan Z, Zhu Z, Zhu F, Ding F, Wang Y, Wang X, Luo X, Yang J, Liu F and Sun D: Impact of human adipose tissue-derived stem cells on dermatofibrosarcoma protuberans cells in an indirect co-culture: An in vitro study. Stem Cell Res Ther. 12(440)2021.PubMed/NCBI View Article : Google Scholar
73	Diao X, Guo C, Zheng H, Zhao K, Luo Y, An M, Lin Y, Chen J, Li Y, Li Y, et al: SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer. Signal Transduct Target Ther. 8(426)2023.PubMed/NCBI View Article : Google Scholar
74	Li Y, Zheng H, Luo Y, Lin Y, An M, Kong Y, Zhao Y, Yin Y, Ai L, Huang J and Chen C: An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. Cancer Commun (Lond). 43:1289–1311. 2023.PubMed/NCBI View Article : Google Scholar
75	Zhang HF, Wang YL, Tan YZ, Wang HJ, Tao P and Zhou P: Enhancement of cardiac lymphangiogenesis by transplantation of CD34⁺VEGFR-3⁺ endothelial progenitor cells and sustained release of VEGF-C. Basic Res Cardiol. 114(43)2019.PubMed/NCBI View Article : Google Scholar
76	Kawai Y, Shiomi H, Abe H, Naka S, Kurumi Y and Tani T: Cell transplantation therapy for a rat model of secondary lymphedema. J Surg Res. 189:184–191. 2014.PubMed/NCBI View Article : Google Scholar
77	Deng J, Dai T, Sun Y, Zhang Q, Jiang Z, Li S and Cao W: Overexpression of Prox1 induces the differentiation of human adipose-derived stem cells into lymphatic endothelial-like cells in vitro. Cell Reprogram. 19:54–63. 2017.PubMed/NCBI View Article : Google Scholar
78	Ou HX, Guo BB, Liu Q, Li YK, Yang Z, Feng WJ and Mo ZC: Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 39:1249–1258. 2018.PubMed/NCBI View Article : Google Scholar
79	Chen DB: Experimental study of bone marrow mesenchymal stem cells (BMSCs) promoting hematopoietic reconstruction and immune regulation POST-HSCT. Fujian Medical University, 2022.
80	Salek Farrokhi A, Zarnani AH, Rezaei Kahmini F and Moazzeni SM: Mesenchymal stem cells induce expansion of regulatory T cells in abortion-prone mice. Reproduction. 161:477–487. 2021.PubMed/NCBI View Article : Google Scholar
81	Gousopoulos E, Proulx ST, Bachmann SB, Scholl J, Dionyssiou D, Demiri E, Halin C, Dieterich LC and Detmar M: Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function. JCI Insight. 1(e89081)2016.PubMed/NCBI View Article : Google Scholar
82	Choi G, Na H, Kuen DS, Kim BS and Chung Y: Autocrine TGF-β1 maintains the stability of Foxp3⁺ regulatory T cells via IL-12Rβ2 downregulation. Biomolecules. 10(819)2020.PubMed/NCBI View Article : Google Scholar
83	Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E and Papadopoulou A: Promises and pitfalls of next-generation treg adoptive immunotherapy. Cancers (Basel). 15(5877)2023.PubMed/NCBI View Article : Google Scholar
84	Mao LL, Yuan H, Wang WW, Wang YJ, Yang MF, Sun BL, Zhang ZY and Yang XY: Adoptive regulatory T-cell therapy attenuates perihematomal inflammation in a mouse model of experimental intracerebral hemorrhage. Cell Mol Neurobiol. 37:919–929. 2017.PubMed/NCBI View Article : Google Scholar
85	Ehyaeeghodraty V, Molavi B, Nikbakht M, Malek Mohammadi A, Mohammadi S, Ehyaeeghodraty N, Fallahi B, Mousavi SA, Vaezi M and Sefidbakht S: Effects of mobilized peripheral blood stem cells on treatment of primary lower extremity lymphedema. J Vasc Surg Venous Lymphat Disord. 8:445–451. 2020.PubMed/NCBI View Article : Google Scholar
86	Białobrzeska M, Stępniewski J, Martyniak A, Szuba A and Dulak J: Generation of human induced pluripotent stem cell line from peripheral blood of patient with lymphedema-distichiasis syndrome. Stem Cell Res. 85(103693)2025.PubMed/NCBI View Article : Google Scholar
87	Ren Y, Kebede MA, Ogunleye AA, Emerson MA, Evenson KR, Carey LA, Hayes SC and Troester MA: Burden of lymphedema in long-term breast cancer survivors by race and age. Cancer. 128:4119–4128. 2022.PubMed/NCBI View Article : Google Scholar
88	Huang Y, Luo L, Xu Y, Li J, Wu Z, Zhao C, Wen J, Jiang P, Zhu H, Wang L, et al: UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia. Cell Death Dis. 16(351)2025.PubMed/NCBI View Article : Google Scholar
89	Deng Y, Lin A, Lai C, He W, Li J, Zhang N, Huang S, Tong L, Lai Y, Huo Y and Xu J: Combined inhibition of importin-β and PBR enhances osteogenic differentiation of BMSCs by reducing nuclear accumulation of glucocorticoid receptor and promoting its mitochondrial translocation. J Steroid Biochem Mol Biol. 250(106731)2025.PubMed/NCBI View Article : Google Scholar
90	Liu Y, Xu W, Liu G, Ma L and Li Z: Therapeutic efficacy of autologous bone marrow mesenchymal stem cell transplantation in patients with spinal cord injury: A meta-analysis. EFORT Open Rev. 10:309–315. 2025.PubMed/NCBI View Article : Google Scholar
91	Xiang Q, Xu F, Li Y, Liu X, Chen Q, Huang J, Yu N, Zeng Z, Yuan M, Zhang Q, et al: Transcriptome analysis and functional identification of adipose-derived mesenchymal stem cells in secondary lymphedema. Gland Surg. 9:558–574. 2020.PubMed/NCBI View Article : Google Scholar
92	Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M and Stojkovic M: Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 15:36–45. 2018.PubMed/NCBI View Article : Google Scholar
93	Yoon YS, Park JS, Tkebuchava T, Luedeman C and Losordo DW: Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 109:3154–3157. 2004.PubMed/NCBI View Article : Google Scholar
94	Lan T, Luo M and Wei X: Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol. 14(195)2021.PubMed/NCBI View Article : Google Scholar
95	Ljujic B, Milovanovic M, Volarevic V, Murray B, Bugarski D, Przyborski S, Arsenijevic N, Lukic ML and Stojkovic M: Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci Rep. 3(2298)2013.PubMed/NCBI View Article : Google Scholar
96	Marcella S, Braile M, Grimaldi AM, Soricelli A and Smaldone G: Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study. Oncol Lett. 29(182)2025.PubMed/NCBI View Article : Google Scholar
97	Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, Yin Y, Zhang Q, Gao F, Wang H, et al: Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: A single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 13(180)2022.PubMed/NCBI View Article : Google Scholar
98	Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S and Rodeghiero F: Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: Present and future. Stem Cell Res Ther. 7(93)2016.PubMed/NCBI View Article : Google Scholar
99	Thongsit A, Oontawee S, Siriarchavatana P, Rodprasert W, Somparn P, Na Nan D, Osathanon T, Egusa H and Sawangmake C: Scalable production of anti-inflammatory exosomes from three-dimensional cultures of canine adipose-derived mesenchymal stem cells: Production, stability, bioactivity, and safety assessment. BMC Vet Res. 21(81)2025.PubMed/NCBI View Article : Google Scholar
100	Xie X, Song Q, Dai C, Cui S, Tang R, Li S, Chang J, Li P, Wang J, Li J, et al: Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: A phase I/II clinical trial. Gen Psychiatr. 36(e101143)2023.PubMed/NCBI View Article : Google Scholar
101	Chu M, Wang H, Bian L, Huang J, Wu D, Zhang R, Fei F, Chen Y and Xia J: Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia. Stem Cell Rev Rep. 18:2152–2163. 2022.PubMed/NCBI View Article : Google Scholar